Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s):  MEDXF

Healthcare
Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.


TSX:MDP - Post by User

Medexus Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(1)
•••
Post by BrokeNewbieon Nov 15, 2016 10:26pm
147 Views
Post# 25466569

taken off ft

taken off ft

Peer analysis

Key Information
Company Revenue (TTM) Net income (TTM) Market cap Employees
Quest PharmaTech Inc 32.61k -5.20m 15.04m 0.00
BELLUS Health Inc 3.82m -377.00k 15.27m 9.00
Aequus Pharmaceuticals Inc 234.18k -5.30m 15.97m --
Avagenesis Corp 0.00 -1.23m 15.99m --
Aptose Biosciences Inc 0.00 -18.38m 16.69m 22.00
Pediapharm Inc 4.04m 738.15k 17.09m --
Antibe Therapeutics Inc 7.07m -3.36m 17.28m 3.00
Microbix Biosystems Inc 8.16m 288.59k 17.79m 20.00
Briacell Therapeutics Corp 0.00 -2.20m 18.50m --
Acasti Pharma Inc 32.04k -9.59m 18.75m 11.00
DiaMedica Inc 0.00 -2.16m 18.76m 0.00
Crescita Therapeutics Inc 741.00k -16.85m 19.51m --

i feel safe invested in this company while comparing it to some of its peer, but yeah im here for long term, positive revenue q2 will just show that the company will keep growing and increase their line of product when oxital gets approved
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities